Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?

por Smit, M. D., Van Gelder, I. C.
Publicado 2011

Non vitamin K anticoagulation drugs will win the race

por Van Gelder, I. C., De With, R. R., Rienstra, M.
Publicado 2016

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands

por Crijns, H. J. G. M., Van Gelder, I. C.
Publicado 2020

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial

por Koldenhof, T, Van Gelder, I C, Crijns, H J G M, Rienstra, M, Tieleman, R G
Publicado 2023

Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation

por Al-Jazairi, M. I. H., Rienstra, M., Klinkenberg, T. J., Mariani, M. A., Van Gelder, I. C., Blaauw, Y.
Publicado 2019

Genetically-determined body mass index and the risk of atrial fibrillation progression in men and women

por Siland, J. E., Nguyen, B. O., de With, R. R., Van Gelder, I. C., van der Harst, P., Rienstra, M.
Publicado 2021

Clustering of cardiovascular and renal comorbidities and risk of incident atrial fibrillation in the community-based PREVEND cohort

por Van Deutekom, C, Geelhoed, B, Van Munster, B C, Bakker, S J L, Gansevoort, R T, Van Gelder, I C, Rienstra, M
Publicado 2023

Stroke risk in patients with device-detected atrial high-rate episodes

por Erküner, Ö., Rienstra, M., Van Gelder, I. C., Schotten, U., Crijns, H. J. G. M., Luermans, J. G. L. M.
Publicado 2017

Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study

por Nguyen, B.O., Meems, L.M.G., van Faassen, M., Crijns, H.J.G.M., van Gelder, I.C., Kuipers, F., Rienstra, M.
Publicado 2021

Reappraisal of Atrial fibrillation: interaction between hyperCoagulability, Electrical remodelling and Vascular destabilisation in the progression of AF (RACE V) Tissue Bank Projec...

por Gilbers, M. D., Bidar, E., Maesen, B., Zeemering, S., Isaacs, A., Crijns, H., van Gelder, I., Rienstra, M., Verheule, S., Maessen, J., Stoll, M., Schotten, U.
Publicado 2021

Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study

por Meems, L.M.G., Artola Arita, V., Velt, M., Dudink, E.A.M.P., Crijns, H.J.G.M., Van Gelder, I.C., Rienstra, M.
Publicado 2022

Cardioversion strategy impacts quality of rate control during recurrences of atrial fibrillation

por Van Der Velden, R, Pluymaekers, N, Dudink, E, Luermans, J, Meeder, J, Lenderink, T, Widdershoven, J, Bucx, J, Rienstra, M, Van Gelder, I, Crijns, H, Linz, D
Publicado 2023

Heart rate increase and inappropriate sinus tachycardia after cryoballoon pulmonary vein isolation for atrial fibrillation

por van Deutekom, C., Mulder, B. A., Groenveld, H. F., Tieleman, R. G., Wiesfeld, A. C. P., Tan, E. S., van Gelder, I. C., Rienstra, M., Blaauw, Y.
Publicado 2021

Planning and monitoring of patients for electrical cardioversion for atrial fibrillation

por Deuling, J. H. H., Vermeulen, R. P., Smit, M. D., van der Maaten, J. M. A. A., Boersema, H. M., van den Heuvel, A. F. M., Van Gelder, I. C.
Publicado 2011

Obesity, epicardial adipose tissue and left atrial cardiomyopathy in patients with heart failure with preserved ejection fraction: a cardiac MRI based study

por Lobeek, M, Gorter, T M, Van Empel, V P M, Manintveld, O C, Tieleman, R G, Maass, A H, Vernooy, K, Westenbrink, B D, Van Gelder, I C, Van Veldhuisen, D J, Rienstra, M
Publicado 2023

PREVENTION-ACHD: PRospEctiVE study on implaNTable cardioverter-defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease; Rationale and Design

por Vehmeijer, J. T., Koyak, Z., Zwinderman, A. H., Harris, L., Peinado, R., Oechslin, E. N., Silversides, C. K., Bouma, B. J., Budts, W., van Gelder, I. C., Oliver, J. M., Mulder, B. J. M., de Groot, J. R.
Publicado 2019

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study

por Van De Lande, M E, Van Deutekom, C, Geelhoed, B, Nguyen, L B O, Tieleman, R G, Weberndorfer, V, Crijns, H J G M, Hemels, M E W, De Melis, M, Schotten, U, Linz, D, Van Gelder, I C, Rienstra, M
Publicado 2023

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V

por Park Frausing, M H J, Van De Lande, M, Maass, A H, Nguyen, B O, Hemels, M E W, Tieleman, R, Koldenhof, T, De Melis, M, Linz, D, Schotten, U, Weberndorfer, V, Crijns, H J G M, Van Gelder, I C, Nielsen, J C, Rienstra, M
Publicado 2023

Recurrent and founder mutations in the Netherlands—Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy

por van der Zwaag, P. A., van Rijsingen, I. A. W., de Ruiter, R., Nannenberg, E. A., Groeneweg, J. A., Post, J. G., Hauer, R. N. W., van Gelder, I. C., van den Berg, M. P., van der Harst, P., Wilde, A. A. M., van Tintelen, J. P.
Publicado 2013

Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study

por Alings, M., Smit, M. D., Moes, M. L., Crijns, H. J. G. M., Tijssen, J. G. P., Brügemann, J., Hillege, H. L., Lane, D. A., Lip, G. Y. H., Smeets, J. R. L. M., Tieleman, R. G., Tukkie, R., Willems, F. F., Vermond, R. A., Van Veldhuisen, D. J., Van Gelder, I. C.
Publicado 2013